Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer

Summary

The goal of this clinical research study is to learn about how effective 2 chemotherapy drugs carboplatin (Paraplatin) plus docetaxel (Taxotere) in the treatment of patients with anaplastic prostate cancer. Patients who continue to have advanced disease will be switched to etoposide (VePesid) plus cisplatin (Platinol-AQ) to study how effective this second line of chemotherapy is in the treatment of patients iwth anaplastic prostate cancer. The side effects, characteristics of patients who respond, and overall survival will also be studied.

Timeline

Start

2006-05

Primary completion

2013-04

Completion

2013-04

Outcome

Met primary endpoint

registry MEDIAN First-Line: Carboplatin + Docetaxel: 5.1 (4.2 to 6.0) months NCT00514540 ↗

registry analysis (unspecified test); First-Line: Carboplatin + Docetaxel vs Second-Line: Etoposide + Cisplatin; p < 0.005; Bayesian probability model NCT00514540 ↗

Publications

• Results Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, Pagliaro LC, Kim J, Millikan RE, Ryan C, Tannir NM, Zurita AJ, Mathew P, Arap W, Troncoso P, Thall PF, Logothetis CJ. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res. 2013 Jul 1;19(13):3621-30. doi: 10.1158/1078-0432.CCR-12-3791. Epub 2013 May 6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Carboplatin	Small molecule	5 unknown	Intravenous
Subject	Cisplatin	Other / unclassified	25 mg/m2	Intravenous
Subject	Docetaxel	Small molecule	75 mg/m2	Intravenous
Subject	Etoposide	Small molecule	120 mg/m2	Intravenous

Indications